News Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement Read More » October 27, 2022 News Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference Read More » October 26, 2022 News Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24 Read More » October 17, 2022 News Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl Read More » October 4, 2022 News Nutriband Inc. Announces Application for Dual Listing on Upstream Read More » October 3, 2022 News Nutriband Inc. Reports Revenue Up 113% YoY in Q2 Read More » September 8, 2022 News Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split Read More » August 16, 2022 News Nutriband Inc. Details of Seven-for-Six Forward Stock Split. Read More » August 10, 2022 News Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA™ Abuse Deterrent Transdermal Technology Patent Read More » August 1, 2022 « Previous Page1 Page2 Page3 Page4 Page5 Next »
News Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement Read More » October 27, 2022
News Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference Read More » October 26, 2022
News Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24 Read More » October 17, 2022
News Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl Read More » October 4, 2022
News Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA™ Abuse Deterrent Transdermal Technology Patent Read More » August 1, 2022